Rhabdoviridae Infections is an indication for drug development with over 60 pipeline drugs currently active. According to GlobalData, preregistered drugs for Rhabdoviridae Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Rhabdoviridae Infections compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rhabdoviridae Infections overview

The family Rhabdoviridae are negatively stranded RNA viruses consisting of two genera that infect animal. The Rhabdoviridae family contains two viruses that infect humans, however, which are rabies virus (RABV) and vesicular stomatitis virus (VSV.) These two viruses are in the lyssavirus and vesiculovirus genera respectively. Rhabdoviridae members replicate in the cytoplasm. They first transcribe a positive RNA template, then use that template to regenerate their negative RNA genome.

For a complete picture of PTSR and LoA scores for drugs in Rhabdoviridae Infections, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.